E1 - Esophageal Cancer Neoadjuvant Comparison

E1   |  12 min   |   Latest   |  Publication Link

• Podcast based on: Deng, S.; Yan, X.; Peng, Y.; Zhu, L.; Shen, Y.; Ying, W.; Xu, Y.; Fu, Z. Three-Year Outcomes of Neoadjuvant Chemoimmunotherapy vs. Neoadjuvant Chemoradiotherapy in Resectable Esophageal Cancer: A Multicenter Retrospective Study. Cancers 2026, 18, 155. https://doi.org/10.3390/cancers18010155
  Type: Article  |  Publication date: 01 January 2026
  
  
• Summary: Evidence regarding neoadjuvant chemoimmunotherapy (nCIT) or neoadjuvant chemoradiotherapy (nCRT) for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) remains controversial. This study (n = 225) investigated the long-term efficacy and safety of nCIT versus nCRT in patients with LA-ESCC. The results suggest that nCIT can improve the long-term survival of patients with resectable esophageal cancer, whereas nCRT may provide greater benefits in patients with node-positive (N+) or non-cT4-stage disease. This study demonstrates the clinical efficacy and safety of nCIT in patients with LA-ESCC.
  
  
• Keywords: locally advanced resectable esophageal squamous cell carcinoma; neoadjuvant chemoradiotherapy; immunotherapy; survival

 

Disclaimer:
This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.